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Abstract
Introduction Candidaemia in critically-ill intensive care unit
(ICU) patients is associated with high crude mortality.
Determinants of mortality – particularly those amenable to
potential modification – are incompletely defined.
Methods A nationwide prospective clinical and microbiological
cohort study of all episodes of ICU-acquired candidaemia
occurring in non-neutropenic adults was undertaken in
Australian ICUs between 2001 and 2004. Multivariate Cox
regression analyses were performed to determine
independently significant variables associated with mortality.
Results 183 episodes of ICU-acquired candidaemia occurred
in 183 patients during the study period. Of the 179 with
microbiological data, Candida albicans accounted for 111
(62%) episodes and Candida glabrata, 32 (18%). Outcome
data were available for 173: crude hospital mortality at 30 days
was 56%. Host factors (older age, ICU admission diagnosis,
mechanical ventilation and ICU admission diagnosis) and failure
to receive systemic antifungal therapy were significantly
associated with mortality on multivariate analysis. Among the
subset who received initial fluconazole therapy (n = 93), the
crude mortality was 52%. Host factors (increasing age and
haemodialysis receipt), but not organism- (Candida  species,
fluconazole MIC), pharmacokinetic- (fluconazole dose, time to
initiation), or pharmacodynamic-related parameters (fluconazole
dose:MIC ratio) were associated with mortality. Process of care
measures advocated in recent guidelines were implemented
inconsistently: follow-up blood cultures were obtained in 68% of
patients, central venous catheters removed within five days in
80% and ophthalmological examination performed in 36%.
Conclusions Crude mortality remains high in Australian ICU
patients with candidaemia and is overwhelmingly related to host
factors but not treatment variables (the time to initiation of
antifungals or fluconazole pharmacokinetic and
pharmacodynamic factors). The role and timing of early
antifungal intervention in critically-ill ICU patients requires further
investigation.
Introduction
Candidaemia is a relatively common healthcare-associated
infection in critically-ill patients in intensive care units (ICUs)
[1-3] that is associated with poor clinical outcomes and
excess economic costs [4,5].
Despite the availability of new antifungal agents and manage-
ment guidelines [6], candidaemia remains associated with
persistently high crude mortality rates. Interest has therefore
centred on potentially modifiable treatment-related outcome
determinants. In particular, improved outcomes among pre-
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dominantly non-ICU patient cohorts have been associated
with earlier initiation of antifungal therapy and for fluconazole
regimens optimised for pharmacodynamic parameters [7-10].
However, the generalisability of these findings to critically-ill
ICU patients remains unknown. We therefore assessed the
association of outcome with host-, microbial-, and treatment-
related factors among a large prospective Australia-wide
cohort of ICU patients with candidaemia. Although the overall
population-based epidemiology of candidaemia in Australia
has been previously reported as part of the Australian Candi-
daemia Study [11], episodes specifically occurring in adult
non-neutropenic ICU patients have now been analyzed and
presented here to describe their outcomes and prognostic
factors.
Materials and methods
Study design
The Australian Candidaemia Study involved a three-year pro-
spective nationwide surveillance of all episodes of candidae-
mia in Australia from August 2001 to July 2004 as reported
elsewhere [11]. Fifty of 52 Australian public and private micro-
biology laboratories participated in the study. Clinical informa-
tion on each episode was collected on a standardised data
form at day 5 and day 30 following the first isolation of Cand-
ida species from blood. Data included patient demographics,
major concomitant conditions, risk factors occurring within the
preceding 30 days (such as surgical and other invasive inter-
ventions, vascular access devices, and receipt of total
parenteral nutrition, haemodialysis, immunosuppressive thera-
pies and antimicrobial agents), source of candidaemia, clinical
signs of sepsis, complications, results of diagnostic studies
(including serum creatinine at days 1 and 5), antifungal ther-
apy and clinical outcomes at 30 days. Candida isolates were
forwarded to reference laboratories for phenotypic and geno-
typic species identification (performed in the National Mycol-
ogy Reference Laboratory, Women's and Children's Hospital,
Adelaide and the Molecular Mycology Reference Laboratory,
Westmead Hospital, Sydney, respectively), and susceptibility
testing using Clinical Standards Laboratory Institutes method-
ology [12] (performed in the National Mycology Reference
Laboratory). Approval for the study was obtained from the
Human Research Ethics Committees of all participating insti-
tutions. Informed written consent was obtained from patients
that were included in the study.
Definitions
The definition of ICU acquisition of candidaemia was the
occurrence of the first positive blood culture growing Candida
species at 48 hours or more following ICU admission or 48
hours or less following ICU discharge. Paediatric, neonatal or
neutropenic (absolute neutrophil count ≤ 1 × 109 neutrophils/
L) patients were excluded. ICUs included hospital wards or
units providing invasive ventilatory and/or intensive haemody-
namic support; high dependency units and coronary care units
were excluded. Risk factors over the 30 days prior to onset of
candidaemia were assessed. Vascular access device-related
candidaemia required the isolation of the same Candida spe-
cies from both blood and catheter tip. Relapses were defined
as recurrent positive blood cultures with the same species
within 30 days of the original positive blood culture after an ini-
tial clinical and microbiological response.
Statistical analyses
Clinical data were analyzed using SPSS (Version 16.0, SPSS,
Chicago, IL, USA). Incidences were calculated using ICU
admission data from participating ICUs covering the study
period. Univariate analyses were performed using the Stu-
dent's t test (continuous variables) and chi-squared or Fisher's
exact tests (categorical variables). Assessment of factors
associated with mortality were performed using multivariate
Cox regression models with hospital mortality as the depend-
ant variable, censored for hospital discharge, using the back-
wards selection method after initially including all biologically-
plausible variables, and those with an unadjusted association
of P < 0.2. A P < 0.05 was set as the limit for acceptance or
removal of variables. For all analyses, the fluconazole dose was
adjusted for renal impairment [13] and the fluconazole mini-
mum inhibitory concentration (MIC) and fluconazole dose:MIC
ratio were log10  transformed. Survival analyses were per-
formed on two separate patient cohorts: the entire ICU cohort
and the subset of patients in whom fluconazole was the sole
initial antifungal therapy during the initial 72 hours of therapy
(but exclusion of patients with breakthrough infection, defined
as occurrence of candidaemia more than 72 hours prior to col-
lection of the first positive blood culture).
Results
Cases and incidence of candidaemia in ICU
Over the three-year study period, there were 183 episodes of
ICU-acquired candidaemia in 183 patients from 38 ICUs. The
mean age ± standard deviation was 58.6 ± 18.6 years and
57% were male. Most patients had undergone a recent surgi-
cal procedure (67%), had received recent antimicrobial ther-
apy (97%) and were ventilated at the time of candidaemia
diagnosis (79%). The median time from ICU admission to
development of candidaemia was eight days (interquartile
range (IQR), 5 to 15 days; range, 2 to 86 days). Almost three-
quarters of episodes (74%) occurred in tertiary-referral hospi-
tal ICUs. The overall incidence of ICU-acquired candidaemia
calculated from 19 ICUs (of the 22 ICUs reporting at least
three candidaemia episodes) ranged from 0.53 to 6.46 per
1000 ICU admissions (mean, 2.06 per 1000 admissions;
95% confidence interval, 1.73 to 2.44).
Species distribution and antifungal susceptibilities
Candida albicans accounted for 62% (111/178) of episodes,
Candida glabrata for 18% (32), Candida parapsilosis for 8%
(14), Candida tropicalis for 6% (10), Candida krusei for 4%
(7), Candida dubliniensis for 1% (2), and other Candida spe-
cies accounted for 3% (5) of episodes. There were two mixedAvailable online http://ccforum.com/content/13/4/R115
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infections (one C. albicans/C. glabrata and one C. glabrata/
unidentified  Candida  species). Antifungal susceptibility
results were available for 174 isolates (Table 1). Based on
Clinical Standards Laboratory Institutes MIC breakpoints [14-
16], all isolates were susceptible to amphotericin B, 167
(96%) to flucytosine, 136 (78%) to fluconazole, 115 (66%) to
itraconazole and 172 (99%) to voriconazole. Of the 32 C. gla-
brata isolates, two (6%) were susceptible to fluconazole, 23
(72%) were susceptible-dose dependent and seven (22%)
were resistant. Two of the fluconazole-resistant isolates were
also resistant to voriconazole. All seven C. krusei isolates were
susceptible to voriconazole. All of the other 135 Candida iso-
lates were fluconazole susceptible with the exception of one
isolate of C. albicans that demonstrated dose-dependent sus-
ceptibility. The MIC90 for caspofungin was 0.25 μg/mL (n =
54: Table 1).
Clinical characteristics, complications and management 
of candidaemia
Manifestations of sepsis [17] were common both at diagnosis
of candidaemia (84%) and at day 5 (76%). The source of can-
didaemia was attributed to an intravascular device in 35%, an
intra-abdominal source in 10%, the urinary tract in 3%, other
sources in 5% and an unknown source in 47%.
Ophthalmological manifestations consistent with intraocular
candidiasis were demonstrated in six of 48 (13%) patients
who underwent ocular examination. Other infective complica-
tions of candidaemia included nine episodes of metastatic
renal infections, three cases of endocarditis (all graded 'possi-
ble' infection by Duke's criteria [18]) and two patients with
hepatosplenic candidiasis (documented by computed tomog-
raphy scan and post-mortem examination). Relapses occurred
in 24 of 183 (13%) episodes. Neither metastatic infective foci
nor relapses were associated with specific Candida species
or any underlying co-morbidity.
Antifungal therapy was initiated in 156 (85%) patients: of
these, fluconazole in 76%, amphotericin B deoxycholate in
12%, a lipid formulation of amphotericin B in 4%, caspofungin
in 4%, and voriconazole or posaconazole in 3%. There was
considerable variation in the time to initiation of antifungal ther-
apy: in 21% it was initiated within 24 hours of drawing the first
positive blood culture, in 14% between 24 and 48 hours, in
29% between 48 and 72 hours, and in 35% greater than 72
hours.
Other processes of care were also assessed. Among patients
surviving five days, follow-up blood cultures were obtained in
68% and central venous catheters removed within five days in
80%. Among patients surviving 30 days, an ocular examination
had been performed in 36% (90% of which were performed
by an ophthalmologist).
Determinants of mortality
Among the entire ICU cohort with outcome data (n = 173), the
crude in-hospital 30-day mortality was 56%, with median time
to death after drawing the first positive blood culture of seven
days (IQR, 2 to 12 days). Variables associated with an
increased risk of death by multivariate Cox regression analyses
Table 1
In vitro antifungal susceptibility of Candida species isolated from ICU-acquired candidaemia episodes
Agent MIC* Candida albicans 
(n = 106)
Candida glabrata 
(n = 32)
Candida krusei 
(n = 7)
Candida parapsilosis 
(n = 14)
Candida tropicalis 
(n = 10)
AMB MIC50 0.125 0.25 0.25 0.5 0.5
MIC90 0.25 0.5 0.5 0.5 0.5
5FC MIC50 0.125 0.03 8 0.125 0.06
MIC90 0.5 0.03 16 0.25 0.125
FLU MIC50 13 2 6 4 2 1
MIC90 26 4 > 6 4 4 4
ITR MIC50 0.06 2 0.5 0.25 0.25
MIC90 0.125 16 0.5 0.5 0.5
VOR MIC50 0.016 0.5 0.5 0.06 0.06
MIC90 0.03 1 0.5 0.25 0.5
POS MIC range 
(no. tested)
0.008 to 0.06 (16) 0.03 to 8 (7) 0.125 (1) - 0.008 to 0.06 (4)
CAS MIC range 
(no. tested)
0.03 to 0.25 (27) 0.06 to 0.25 (11) 0.25 to 1 (3) 0.125 (1) 0.06 to 0.5 (7)
AMB = amphotericin B; CAS = caspofungin; 5FC = 5-flucytosine; FLU = fluconazole; ITR = itraconazole; POS = posaconazole; MIC = minimum 
inhibitory concentration (μg/mL); VOR = voriconazole.Critical Care    Vol 13 No 4    Marriott et al.
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are presented in Table 2: those independently associated by
multivariate analysis included host-related factors (increasing
age, mechanical ventilation at time of candidaemia and man-
agement in the ICU for reasons other than multitrauma) and
non-receipt of systemic antifungal therapy. Several other host-
related factors (total parenteral nutrition, receipt, haemodialy-
sis receipt and presence/non-removal of vascular access
devices) were also associated with mortality on univariate –
but not multivariate – analysis. Of note was the lack of associ-
ation with mortality for different Candida species or for delays
in initiation of antifungal therapy.
Among the subset of patients who received initial fluconazole
therapy for the first 72 hours (n = 93), crude mortality was
52%. Variables independently associated with increased risk
of death by multivariate Cox regression analysis included
increasing age and haemodialysis receipt (Table 3). Although
there was a non-significant trend between time to initiation of
fluconazole and mortality (Table 4), this was not significant by
multivariate analysis. Organism-related (Candida species and
fluconazole MIC), pharmacokinetic-related (renal-adjusted flu-
conazole dose) or pharmacodynamic-related (fluconazole
dose:MIC ratio) factors were not associated with mortality.
Discussion
The serious consequences of candidaemia among critically-ill
patients in the ICU [4,5] are apparent in this three-year nation-
wide study, with crude in-hospital 30-day mortality rates of
56% and a median time from candidaemia to death of seven
days. To improve these poor outcomes, the identification of
potentially modifiable determinants of mortality is an urgent pri-
ority. Recent observational studies on mixed ICU/non-ICU
cohorts with candidaemia have reported associations
between mortality and delays in initiation of antifungal therapy
and fluconazole regimens not optimised for target pharmaco-
dynamic parameters [7-10]. We thus sought to assess
whether these – or other – potentially modifiable factors were
associated with mortality among critically-ill ICU patients with
candidaemia.
As expected, among the entire cohort of candidaemic ICU
patients, multivariate survival analysis revealed that host-
Table 2
Risk factors for hospital mortality on entire ICU cohort with candidaemia
Variable Dying patients* Surviving patients* Univariate analysis** Multivariate analysis†
Unadjusted HR 
(95% CI)
P Adjusted HR (95% 
CI)††
P
Male sex 55/97 (57%) 45/76 (59%) 1.00 (0.67 to 1.49) 0.99
Age 63.3 ± 16.7 years 51.1 ± 19.2 years 1.03 (1.01 to 1.04) <0.001 1.03 (1.01 to 1.4) <0.001
Antifungal agents prior to 
diagnosis
10/96 (10%) 6/76 (8%) 1.03 (0.53 to 1.98) 0.93
Non-receipt of antifungal 
agents after diagnosis
20/97 (21%) 5/76 (7%) 5.17 (3.08 to 8.68) <0.001 7.90 (3.73 to 16.71) <0.001
Candida albicans 43/97 (44%) 26/76 (34%) 0.73 (0.49 to 1.10) 0.13
Vascular access device 
removed or not in place
55/80 (69%) 64/79 (84%) 0.41 (0.26 to 0.67) <0.001
TPN receipt 53/96 (55%) 26/76 (34%) 1.52 (1.02 to 2.28) 0.04
Haemodialysis 23/97 (24%) 8/76 (11%) 1.66 (1.04 to 2.66) 0.03
Corticosteroid receipt 33/97 (34%) 20/76 (26%) 1.36 (0.89 to 2.07) 0.17
Non-multitrauma patient 93/97 (96%) 60/76 (79%) 3.25 (1.19 to 8.87) 0.02 6.97 (1.64 to 29.67) 0.009
Recent surgery 71/97 (73%) 47/76 (62%) 1.24 (0.79 to 1.94) 0.35
Other healthcare related 
infections
73/97 (75%) 55/76 (72%) 0.85 (0.53 to 1.35) 0.49
Ventilation at day 1 82/96 (85%) 55/76 (72%) 1.51 (0.86 to 2.67) 0.15 4.03 (1.93 to 8.41) <0.001
Sepsis at day 1 86/97 (89%) 60/76 (79%) 1.33 (0.71 to 2.49) 0.37
Time to initiation of systemic 
antifungal
2.0 ± 1.3 days 2.3 ± 1.6 days 0.88 (0.75 to 1.04) 0.13
* n/N (%) or mean ± standard deviation shown; **Only significant (P < 0.05) and selected non-significant variables on univariate analysis are 
shown; †Only significant variables on multivariate analysis are shown; ††Adjusted for other variables in the model.
CI = confidence interval; HR = hazard ratio; ICU = intensive care unit; TPN = total parenteral nutrition.Available online http://ccforum.com/content/13/4/R115
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related variables (including age, non-multitrauma patients and
ventilation) and failure to receive antifungal therapy were asso-
ciated with mortality. More than one-quarter of deaths involved
patients not treated with antifungals; more than two-thirds of
whom died within 48 hours of candidaemia onset (i.e. prior to
blood culture positivity). Failure to initiate early antifungal ther-
apy clearly represents a potentially modifiable mortality risk
factor, and in this regard, predictive models to prospectively
identify patients at high risk of candidaemia [19,20] as a trig-
ger for early antifungal intervention may improve outcomes.
However, it was of considerable interest that among treated
patients in our cohort, delays in the initiation of antifungal ther-
apy were not associated with greater mortality. Given recent
reports of such an association [8,9], and the Infectious Dis-
eases Society of America (IDSA) [21] guidelines, which rec-
ommend initiation of antifungal therapy within 24 hours of
diagnosis, our discrepant findings require further examination.
Several factors may be relevant. We measured time to antifun-
gal initiation in 24-hour increments, which may therefore have
concealed a beneficial effect of very early treatment, given the
12-hour window period defined by Morrell and colleagues for
a mortality difference [9]. However, it should be noted that in
the study by Morrell and colleagues, only nine patients actually
received antifungal therapy within 12 hours, and that across all
other time periods, no progressive mortality increase was evi-
dent. In contrast, the other relevant study [8] did demonstrate
increases in mortality for delays measured in 24-hour incre-
ments. Both published studies [8,9], however, included a
majority of episodes that were not ICU-acquired among whom
Table 3
Risk factors for hospital mortality on ICU patients with candidaemia initially treated with fluconazole
Variable Dying patients, n (%) Surviving patients, n 
(%)
Univariate analysis* Multivariate analysis**
Unadjusted HR 
(95% CI)
P Adjusted HR (95% CI) P
Age 1.03 (1.01 to 1.05) 0.001 1.03 (1.01 to 1.05) 0.002
Haemodialysis receipt 10/48 (21%) 4/45 (9%) 1.65 (0.82 to 3.32) 0.16 2.12 (1.03 to 4.35) 0.04
TPN receipt 30/48 (63%) 15/45 (33%) 1.90 (1.06 to 3.42) 0.03
Non-multitrauma patient 47/48 (98%) 33/45 (73%) 9.35 (1.29 to 67.84) 0.03
Ventilation day 1 40/48 (83%) 34/45 (76%) 1.28 (0.60 to 2.75) 0.52
Candida glabrata or 
Candida krusei
11/48 (23%) 3/45 (7%) 2.31 (1.17 to 4.56) 0.02
Time to fluconazole 
initiation
1.80 ± 1.29 days 2.51 ± 1.74 days 0.80 (0.65 to 0.98) 0.03
Fluconazole MIC (log10 
transformed)
0.24 ± 0.74 0.10 ± 0.68 1.31 (0.90 to 1.90) 0.16
Fluconazole dose (log10 
transformed)
2.66 ± 0.22 2.62 ± 0.21 1.89 (0.52 to 6.82) 0.33
Fluconazole dose: MIC 
(log10 transformed)
2.33 ± 0.22 2.45 ± 0.72 0.77 (0.54 to 1.11) 0.16
CI = confidence interval; HR = hazard ratio; ICU = intensive care unit; MIC = minimum inhibitory concentration; TPN = total parenteral nutrition.
Table 4
Relationship between time to initiation of fluconazole and mortality
Time to initiation of fluconazole following date initial positive blood culture Hospital mortality, n/N (%)
0 8/15 (53%)
1 days 10/15 (67%)
2 days 15/25 (60%)
3 days 6/16 (38%)
≥4 days 5/16 (31%)Critical Care    Vol 13 No 4    Marriott et al.
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crude hospital mortality rates were about 30%; whereas in our
cohort, all episodes were ICU-acquired and the crude mortal-
ity rate was 56%. Thus, among more critically-ill patient
cohorts, it is possible that any relation between antifungal ini-
tiation and outcome may be either confounded (as antifungal
therapy is more likely to be initiated earlier in patients with
greater disease acuity than in less ill patients) or masked
(given that the severity of underlying disease acuity may be the
principal predictor of mortality rather than candidaemia or the
timing of its treatment).
Optimisation of antifungal regimens represents another poten-
tially important influence on outcome. Several observational
studies have defined target pharmacodynamic parameters for
fluconazole; including an area under the curve:MIC ratio of 55
and weight normalised dose/MIC ratio of 12, with increased
mortality for regimens below these targets [7,10]. However,
among our cohort of fluconazole-treated patients, there was
no association between outcome and MIC, dose or dose:MIC
ratio. Although we were able to adjust fluconazole doses for
renal impairment (based on serum creatinine measurements at
days 1 and 5), we were not able to adjust for body weight. As
above, case mix and severity of illness differences are likely to
also be important: in contrast to our cohort, the previous pub-
lished study cohorts included a minority of ICU patients and
overall mortality rates were low (19 to 28%) [7,10]. Taken
together, our findings indicate that while optimisation of the
timing and dosing of antifungal regimens is clearly an impor-
tant goal, they may only provide an outcome benefit to patients
with moderate illness severity. Conversely, among critically ill
patients, even early optimised antifungal regimens after clinical
manifestations of candidaemia may not influence outcome.
Indeed outcomes might best be improved by antifungal ther-
apy initiation occurring prior to – rather than after – the diag-
nosis of candidaemia. In this regard, clinical prediction
algorithms and more sensitive early diagnostic techniques may
assist in guiding early antifungal intervention.
Authoritative guidelines, such as those published by the IDSA
[21] and the Australasian Society for Infectious Diseases [22],
suggest a number of quality improvement ancillary measures
which aim to improve the outcome of candidaemia. These
include removal of central venous catheters, follow-up blood
cultures and routine ophthalmological examination. Although
only limited observational data [23] suggest a clinical and mor-
tality benefit associated with removal of intravascular cathe-
ters, it remains generally advocated. In the present study,
three-quarters of patients had intravenous catheters removed
within five days of candidaemia onset, suggesting that such
guidelines are generally but not universally accepted among
clinicians. Other advocated strategies were even less fre-
quently adopted: repeat blood cultures to document clear-
ance of candidaemia were performed in only two-thirds of
patients; only two-thirds of surviving patients received at least
10 days of antifungal therapy; and an ophthalmological exam-
ination was performed in one-third. Of those undergoing oph-
thalmological examination, 13% had lesions consistent with
ocular involvement. Although such lesions may be nonspecific
[24], if present, prolongation of antifungal therapy is recom-
mended [21] and vitrectomy with intravitreal antifungal therapy
may be required. These findings indicate that despite general
support for invasive candidiasis management guidelines, fur-
ther efforts are required to improve their implementation.
Although this study includes clinical and epidemiological data
on a large number of ICU-acquired candidaemia episodes
across an entire country, its limitations should be recognised.
Illness acuity scores, such as Acute Physiology and Chronic
Health Evaluation II scores, were not collected, precluding
adjustment of the analyses of prognostic factors associated
with candidaemia outcome. However, other markers of illness
acuity, such as mechanical ventilation, manifestations of sep-
sis, renal function and invasive procedures were measured
and were included in these analyses. Given that no information
on non-candidaemic ICU patients was available, the risk fac-
tors for, and attributable consequences of candidaemia
among Australian ICU patients remain undefined. Further-
more, we could not accurately determine the incidence of met-
astatic infective complications associated with candidaemia
given the observational nature of the study and the inconsist-
ent performance of ophthalmological, radiological, microbio-
logical and other investigations.
Conclusions
In summary, this first nationwide study of candidaemia in criti-
cally ill ICU patients has provided important information on the
epidemiology, clinical management and outcome of ICU-
acquired candidaemia. In particular, it suggests that optimisa-
tion of the timing and dosing regimens of culture-directed anti-
fungal therapy may not be sufficient to yield improvements in
clinical outcome among critically ill ICU patients; rather empir-
ical or preemptive therapy may be required. Furthermore,
implementation of strategies to improve and evaluate adher-
ence to guidelines is essential.
Key messages
￿  The outcomes of ICU-acquired candidaemia remains 
poor, with a crude mortality of 56%.
￿  Among treated patients, host factors, rather than organ-
ism-related, pharmacokinetic-related or pharmacody-
namic-related factors, are associated with mortality.
￿  The timing and role of early antifungal therapy in criti-
cally-ill ICU patients requires further assessment.
￿  Strategies are required to improve the implementation 
of recently published antifungal guidelines.Available online http://ccforum.com/content/13/4/R115
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